LAWSUITS NEWS & LEGAL INFORMATION
Maxipime
The FDA issued an early communication about the ongoing review of new safety data and the request for additional data to further evaluate the risk of death in patients treated with Cefepime. An article in the May 2007 issue of The Lancet Infectious Diseases (Efficacy and safety of Cefepime: a systematic review and meta analysis) raised the question about increased mortality with the use of Cefepime, a broad spectrum B-lactam antibiotic currently approved for the treatment of a variety of infections due to susceptible strains of microorganisms.
The article describes a higher all-cause mortality in patients treated with Cefepime compared to other B-lactam antibiotics. Until FDA's evaluation is completed, healthcare professionals who are considering the use of cefepime should be aware of the risks and benefits described in the product's prescribing information and the new information from this meta-analysis.
Published on Nov-15-07
The article describes a higher all-cause mortality in patients treated with Cefepime compared to other B-lactam antibiotics. Until FDA's evaluation is completed, healthcare professionals who are considering the use of cefepime should be aware of the risks and benefits described in the product's prescribing information and the new information from this meta-analysis.
Maxipime Legal Help
If you or a loved one has suffered damages in dangerous drug case, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.Published on Nov-15-07
READ MORE Drugs/Medical Settlements and Legal News
READER COMMENTS
Veronica R Thompson
on
My mom died that night. A black-brownish liquid came out of her mouth before passing. I believe my mom had a toxic death due to Cefepine. How can her blook lab change dramatically hours after Cefepine was given to her. Why was Cefepine given to her if she had renal failure? Why didn’t medical personnel inform me that Cefepine is dangerous to renal failure patients.